Carcinoma, Pancreatic Ductal Clinical Trial
Official title:
Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas
Ductal adenocarcinoma of the pancreas is the fifth leading cause of cancer related deaths in
the European Union. Tumor markers CA19-9 and carcinoembryonic antigen are important
components in decision making and follow-up of patients diagnosed with this disease.
These tumor markers were found to be elevated not only in the serum but also in other body
fluids in patients with malignant lesions of the parotid gland and the urinary tract. The
authors have described in a previews small preliminary study a positive and a strong linear
correlation between the levels of CA19-9 in urine and saliva with those presented in the
serum of patients with ductal adenocarcinoma of the pancreas. The current study seeks to
enlarge the study population to confirm the previous results and standardize the measured
levels of CA19-9 in these body fluids.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03500068 -
Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study.
|
N/A | |
| Not yet recruiting |
NCT05489458 -
Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy
|
||
| Recruiting |
NCT02310230 -
An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy
|
N/A | |
| Completed |
NCT01478685 -
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT03513705 -
Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1)
|
N/A | |
| Completed |
NCT01808638 -
Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT00226746 -
Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT03432624 -
Detection of MicroRNA-25 in the Diagnosis of Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT02451384 -
According CTC to Compare the Influences of Different Methods to Remove the PDAC
|
N/A | |
| Recruiting |
NCT02529579 -
Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06447662 -
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
|
Phase 1 | |
| Completed |
NCT00471146 -
Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
|
Phase 3 | |
| Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
| Terminated |
NCT01413451 -
Amatuximab for High Mesothelin Cancers
|
Early Phase 1 | |
| Recruiting |
NCT03403101 -
The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT02928081 -
Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma
|
N/A | |
| Completed |
NCT05723978 -
Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
|
||
| Completed |
NCT02150746 -
Circulating Tumor Cells in Operative Blood
|
N/A | |
| Completed |
NCT04146441 -
Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT05621824 -
A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS
|